Navigation Links
GeoVax Labs' CEO Update Letter to Shareholders
Date:1/9/2012

potential revenue value of such a product are in excess of $4 billion annually.

Preventative Vaccine Program

We are extremely fortunate to have the U.S. National Institutes of Health (NIH)-supported HIV Vaccine Trials Network (HVTN) continuing to conduct and fund our preventative vaccine trials. During 2011, several milestones were accomplished: (a) the publication of the results of our phase 1 clinical trial involving 120 participants, (b) the completion of enrollment of our phase 2a trial involving 300 participants and, (c) preparations for launching human clinical testing of the GM-CSF-adjuvanted form of our vaccine.

In the non-human primate model, the adjuvanted vaccine, which co-expresses GM-CSF in the DNA priming component, has shown outstanding and long lasting prevention (not just control) of infection. Because of its superior ability to prevent infection, our plan is to take the adjuvanted vaccine into efficacy trials launched as soon as late 2013.

Last month, it was announced that an application for FDA approval is being sought for a once-daily drug to reduce the risk of HIV infection among uninfected adults. While this made headlines and is a wonderful step toward the prevention of HIV infection, this is not a long-term practical solution to prevent infection. Medication and physician costs, side effects and patient compliance continue to be significant issues that such a drug regimen doesn't adequately address. Although you will read that individuals can achieve 73% protection if they faithfully take this drug, required strict adherence to the necessary prescribed drug therapy is rare. Once a vaccine is available, this method of prevention will no longer be an attractive option.  Similar to the market value for a therapeutic vaccine, current market estimates for a preventative vaccine exceed $4 billion annually.

An article in Nature published this month by researchers at Harvard Medical School
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. GeoVax Labs First Patient Inoculated in Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine
2. GeoVax Phase 2a Clinical Trial Completes Enrollment
3. GeoVax $3.6 Million Award Increased to $4.4 Million by U.S. Government
4. GeoVax Labs, Inc. Announces Second Quarter Financial Results
5. GeoVax Labs HIV/AIDS Vaccine Development Leadership to be Highlighted During 2011 World Vaccine Congress
6. GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases
7. GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine
8. David A. Dodd Appointed Chairman of the Board of GeoVax Labs
9. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
10. GeoVax Awarded Federal Grant Under the Qualifying Therapeutic Discovery Project Program
11. GeoVax Labs Engages The Investor Relations Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... 2011 Hill-Rom Holdings, Inc. (NYSE: HRC ) announced ... second quarter dividend of $0.1025 per share. This dividend is payable ... 17, 2011.   ABOUT HILL-ROM HOLDINGS, ... and provider of medical technologies and related services for the health ...
... and SYDNEY, March 7, 2011 HeartWare International, Inc. ... innovator of less invasive, miniaturized circulatory support technologies that ... announced that CEO Doug Godshall is scheduled to make ... Healthcare Conference at 8:00 a.m. Eastern Time on Tuesday, ...
Cached Medicine Technology:HeartWare to Present at the Barclays Capital 2011 Global Healthcare Conference 2
(Date:4/18/2014)... researchers have been awarded two-year grants for their work ... month. Of the 110 initial submissions to the new ... only four projects were funded, three of which are ... M.D., Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, ... oncology, will use his $500,000 proof of principle grant ...
(Date:4/18/2014)... French . ... regenerative medicine. A team led by Ludwik Leibler from ... and Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle ... that the principle of adhesion by aqueous solutions of ... organs and tissues. This easy-to-use gluing method has been ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... recent papers by a University of Colorado School ... develop treatments or vaccines for Dengue fever, West ... disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, associate ... School of Medicine and an early career scientist ... recently published articles in the scholarly journals ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... By Amanda Gardner HealthDay Reporter , MONDAY, July ... evidence proving that staying in shape and eating right are ... that over 8 million Americans have histories of heart attack, ... the message seriously. That,s the theme of a new ...
... about clinical trials for drugs that have been approved ... health risks, an independent committee at the Institute of ... has developed a conceptual framework to guide the agency ... drug-safety trials. The recommendations of the committee, requested ...
... Parkinson disease patients aren,t walking talls ... alleviated with drugs that target dompamine, a chemical in ... and therefore known as a neurotransmitter. However, such drugs ... commonly affect individuals with severe and advanced forms of ...
... Calif., July 12, 2010 UC Irvine public health ... in impoverished reaches of China, Myanmar and Thailand, thanks ... of a seven-year, $14.5 million award to Pennsylvania State ... Diseases. Yan will collaborate with Penn State principal investigator ...
... Drinking tart cherry juice daily could help reduce the severity ... according to a new study published in the Journal ... University of Pennsylvania, University of Rochester and VA Center of ... of 15 older adults. The adults drank 8 ounces of ...
... that roams with only limited control among the rural poor ... cruzi is the triatomine insect, or "kissing bug," which thrives ... sucks the blood of mammals, helping T. cruzi ... to lie on porches or other areas easily accessible to ...
Cached Medicine News:Health News:Lifestyle Interventions Needed to Stay Heart-Healthy 2Health News:Lifestyle Interventions Needed to Stay Heart-Healthy 3Health News:Hopkins faculty lead development of report to FDA on ethical, scientific issues related to 'post-market' clinical trials 2Health News:Hopkins faculty lead development of report to FDA on ethical, scientific issues related to 'post-market' clinical trials 3Health News:JCI online early table of contents: July 12, 2010 2Health News:JCI online early table of contents: July 12, 2010 3Health News:JCI online early table of contents: July 12, 2010 4Health News:JCI online early table of contents: July 12, 2010 5Health News:JCI online early table of contents: July 12, 2010 6Health News:JCI online early table of contents: July 12, 2010 7Health News:JCI online early table of contents: July 12, 2010 8Health News:New study suggests tart cherry juice can be a natural solution for insomnia 2Health News:Dogs may help collar Chagas disease 2
... on/off switch which allows user to stop rotor ... hinge, with stainless steel pin is virtually indestructible. ... Spins 6 microcentrifuge tubes at low to medium ... g. 6 inch x 6 inch footprint. Starts ...
Inquire...
Spectrafuge 16M High speed microcentrifuge. High g-force for molecular biology applications. Brushless, maintenance-free motor. Easy to use control panel. Complete with 18 x 1.5/2.0 ml rotor. StripSp...
... Powerful single rotation speed of 10,000 ... (x g) , Pellets single- and double-stranded ... and continuous spinning , 12-position rotor holds ... 1.5-ml microcentrifuge tubes , Replaceable rotor ...
Medicine Products: